Pharma: Page 2

  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive
    Image attribution tooltip

    JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

    Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

    By , , • Jan. 14, 2025
  • A flag flies above the headquarters campus of Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly blames slower-than-expected growth for 2024 sales miss

    The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.

    By • Jan. 14, 2025
  • Single strand ribonucleic acid, RNA research Explore the Trendline➔
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Trendline

    The expanding world of RNA therapies

    Medicines from Alnylam, Ionis, Moderna and others have proven the power of RNA in medicines. A growing field of startups is advancing alongside them.

    By BioPharma Dive staff
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive
    Image attribution tooltip

    JPM25: Deals, Summit’s bravado and gene therapy headwinds

    Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers after a difficult year. 

    By , , • Updated Jan. 14, 2025
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

    Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

    By , • Updated Jan. 13, 2025
  • 3 people wearing lab coats and hairnets
    Image attribution tooltip
    Permission granted by Almac Clinical Services
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    Lack of regulatory harmonization and other challenges facing clinical services organizations in the APAC market

    How clinical services organizations are overcoming challenges in the APAC market.

    Jan. 13, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

    Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

    By BioPharma Dive staff • Jan. 10, 2025
  • A picture of President-elect Donald Trump standing behind a podium at a press conference with two American flags in the background.
    Image attribution tooltip
    Scott Olson/Getty Images via Getty Images
    Image attribution tooltip

    5 questions facing pharma in 2025

    Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

    By , , • Jan. 9, 2025
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer says menopause drug succeeds in breast cancer study

    The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.

    By • Jan. 9, 2025
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    RSV vaccines

    FDA adds warning to RSV shots from GSK, Pfizer

    The regulator is requiring labeling that warns of Guillan-Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

    By • Jan. 8, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

    The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.

    By BioPharma Dive staff • Jan. 8, 2025
  • Abstract background to represent molecules.
    Image attribution tooltip

    Mi-Tah / Shutterstock

    Image attribution tooltip
    Sponsored by Esperion Therapeutics

    An evolution in leadership and vision for this pharma company

    Esperion CEO Sheldon Koenig reflects on personal challenges and advancing innovative heart therapies.

    Jan. 6, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

    Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.

    By BioPharma Dive staff • Jan. 2, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Ionis gets a milestone approval; Another top FDA official to step down

    The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.

    By BioPharma Dive staff • Dec. 20, 2024
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Novo’s next-gen obesity drug misses expectations in closely watched trial

    Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.  

    By • Updated Dec. 20, 2024
  • Illustration of a blood clot blocking red blood cells within an artery or a vein.
    Image attribution tooltip
    libre de droit via Getty Images
    Image attribution tooltip

    Regeneron says study data support big bet on new blood thinners

    The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials. 

    By • Dec. 19, 2024
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis shutters MorphoSys sites, lays off staff

    While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.

    By • Dec. 19, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip
    Obesity drugs

    Merck moves into obesity with deal for Hansoh’s GLP-1 pill

    News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

    By • Dec. 18, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Tessera gets sickle cell funding; Corvus shares slide on eczema data

    The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.

    By BioPharma Dive staff • Dec. 18, 2024
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    Pfizer predicts stability, to Wall Street’s relief

    The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty caused by COVID [is] mostly resolved,” its CFO said.

    By • Dec. 17, 2024
  • A white sign bears the word Sanofi at a road entrance to an office building.
    Image attribution tooltip
    JHVE Photo via Getty Images
    Image attribution tooltip

    Sanofi, Teva say study results show gut disease drug could be ‘best in class’

    Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

    By • Dec. 17, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Novo builds up manufacturing; Pepgen Duchenne trial put on hold

    Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.

    By BioPharma Dive staff • Dec. 16, 2024
  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Sundry Photography via Getty Images
    Image attribution tooltip

    Merck calls quits on two immunotherapies for cancer

    The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.

    By • Dec. 16, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO

    Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi. 

    By BioPharma Dive staff • Dec. 13, 2024
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With new data, Lilly sets pace for next wave of breast cancer drugs

    While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.

    By • Updated Dec. 11, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    BenevolentAI restructures; Lilly preps $15B buyback program

    The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

    By BioPharma Dive staff • Updated Dec. 17, 2024